Omega Pharma, part of the 21 Invest portfolio since February 2024, has signed an agreement to acquire Cieffe Derma (“Cieffe”), marking its second strategic acquisition aimed at expanding its presence in dermatology.

Founded in 1995 and based in Northern Italy, Omega Pharma is a leader in the Italian food supplements industry, recognized for its innovation, quality, and scientific excellence. The company operates across several therapeutic areas, including angiology, gastroenterology, urology, gynecology, ophthalmology, and pediatrics.

With the acquisition of Cieffe, Omega Pharma will also expand its footprint into the dermatology sector.

Cieffe, established in 2000 by Salvatore Frontera and based in Northern Italy, develops and markets scientifically supported products with a strong focus on dermatology. Its portfolio includes a broad range of clinically-backed solutions for conditions such as dermatitis, mycoses, and acne, as well as products for general skin and hair care.

The acquisition of Cieffe strengthens Omega Pharma’s national presence by adding 40 scientific representatives to its team and enables the group to enter the rapidly growing dermatology sector. Cieffe’s business model, centered on delivering scientific medical information exclusively to medical specialists, is closely aligned with Omega Pharma’s own approach. Going forward, the group will increase investments in R&D, accelerate digital sales, support international expansion, and create cross-selling opportunities across its therapeutic areas.

Salvatore Frontera, founder and CEO of Cieffe, will remain in his role to ensure continuity during the integration phase and will reinvest part of the proceeds into the parent company.

Following the integration of Cieffe, Omega Pharma expects to exceed €M 40 in revenue in 2025, supported by a nationwide network of 200 scientific representatives. While pharmacies will remain the primary sales channel, digital platforms and exports are expected to play an increasingly significant role.

Andrea Mazzucato, Managing Partner of 21 Invest, comments: “This transaction marks a major milestone in Omega Pharma’s journey to becoming Italy’s leading provider of scientific medical information for dietary supplements. With its robust scientific approach and dermatological expertise, Cieffe is an ideal partner for the growth strategy we are implementing."

Gianantonio Tomaselli, CEO of Omega Pharma, adds: “With Cieffe and Salvatore Frontera, we share a commitment to long-term sustainability and scientific rigor in R&D—values that have made the company a benchmark in the Italian dermatology market. By joining forces, we aim to accelerate growth and further consolidate our market leadership, fully aligned with the strategic vision we share with 21 Invest."